Market revenue in 2022 | USD 51.0 million |
Market revenue in 2030 | USD 180.3 million |
Growth rate | 17.1% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.06% in 2022. Horizon Databook has segmented the South Africa cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Since 2013, regulatory legislations exist in South Africa. The stringent regulatory norms are majorly concerned with use of adult stem cells, induced pluripotent stem cells, and embryo-derived stem cells. This may impede adoption of mesenchymal stem cell therapies in the country.
Moreover, researchers and scientists in the country are working together to undertake initiatives to develop stem cell therapies for life-threatening diseases like cancer, HIV, and others. Furthermore, the country has made significant progress in cell and gene therapy over the past years.
In September 2019, the 5th National Cell and Gene Therapy Meeting was held at the Innovation Hub in Pretoria. As per the symposium panel discussion, South Africa is a key contender in cell and gene therapy research.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into South Africa cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account